NEW YORK (GenomeWeb News) – Genome customization firm Cellectis bioresearch today announced it has won a five-year, $9.5 million contract from the National Institutes of Health for work directed at induced pluripotent stem cells.

Under the terms of the contract, Cellectis bioresearch will provide services to NIH and certain other government agencies. The company will generate iPS cell lines of clinical grade and differentiate iPS cells toward specific tissue cell type of clinical grade.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.